XORTX Therapeutics Inc ( (TSE:XRTX) ) has issued an announcement.
XORTX Therapeutics Inc. has announced an update regarding its communications with the FDA, aiming to accelerate the development of its XRx-026 program for gout treatment. The company is preparing for a Type B meeting with the FDA to discuss the readiness of its XORLO™ drug formulation for a New Drug Application, which could significantly impact its market positioning by providing a much-needed therapeutic option for gout sufferers and potentially transforming the company into a revenue-positive state.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies for progressive kidney disease and gout. The company is working on advancing its proprietary drug formulation, XORLO™, which is aimed at treating gout, a condition with significant unmet medical needs.
YTD Price Performance: -18.67%
Average Trading Volume: 7,755
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: C$4.7M
For detailed information about XRTX stock, go to TipRanks’ Stock Analysis page.